Rijnstate Hospital
Arnhem, Gelderland, Netherlands
NCT Number: NCT00688077
Introduction:
Based on our experience with calcitonin as an FGF-23 suppressive agent in a patient with an FGF-23 producing tumor we hypothesize that calcitonin may be a physiologically important regulator of FGF-23 production and secretion in healthy humans.
Aim:
In this study we wish to examine the FGF-23 suppressive effects of calcitonin in healthy men.
Study Design:
placebo-controlled, cross-over study
Method:
* All twelve subjects are examined on two occasions, once after exposure to placebo 1 ml NaCl 0.9% subcutaneously, and once following calcitonin 200 IU/ml subcutaneously * On both occasions frequent bloodsampling will take place, out an indwelling catheter in de forearm vein. * Sampling times: -15, 0, 60, 120, 240, 360, and 480 minutes * Mealtimes: Calcium and Phosphate intake standardized on both occasions * All samples are analyzed for FGF-23, using a C-terminal FGF-23 ELISA kit (Immunotopics, San Clemente, USA) that measures intact and C-terminal fragments of FGF-23, and one that measures only intact FGF-23 * Samples obtained at T-15, T0, T240 and T480 are stored for later analysis of Ca, albumin, PO4, PTH, 25-OHD and 1,25-OHD
Endpoint:
A change of 25% in de serum FGF-23 levels in response to a single subcutaneous injection of calcitonin 200 IU.
Looking for future studies?
Notify Me20 year–55 year
Male
Interventional
Not applicable
Arnhem, Gelderland, Netherlands
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Calcitonin 200 IU/ml, single subcutaneous injection, experimental group
NaCl 0,9 % 1ml, single subcutaneous injection, placebo group
Time frame: eight hours
Rijnstate Hospital
Other
Evaluation of FGF-23 Suppressibility by Calcitonin in Healthy Men - Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06344546
Critical Illness, Disease Attributes
Prague, Czechia
View Trial DetailsNCT05909722
Hypophosphatemia, Metabolic Diseases
Tartu, Estonia
View Trial DetailsNCT05098249
Anemia, Anemia, Hypochromic
Zurich, Switzerland
View Trial DetailsNCT03489993
Avitaminosis, Bone Diseases
Winston-Salem, North Carolina, United States
View Trial Details